Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATHER: Short-Cycle Therapy in Young People with HIV
NCT01641016Phase 3Unknown
- Sponsor
- Penta Foundation
- Start
- Apr 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Penta Foundation. Primary endpoint: HIV-1 RNA >= 50 copies/ml at 48 weeks. Status: unknown.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01641016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01641016.